1. Home
  2. SXTP vs ARTL Comparison

SXTP vs ARTL Comparison

Compare SXTP & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 60 Degrees Pharmaceuticals Inc.

SXTP

60 Degrees Pharmaceuticals Inc.

HOLD

Current Price

$1.49

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$3.19

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXTP
ARTL
Founded
2010
2011
Country
United States
United States
Employees
3
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SXTP
ARTL
Price
$1.49
$3.19
Analyst Decision
Strong Buy
Hold
Analyst Count
3
2
Target Price
$17.60
N/A
AVG Volume (30 Days)
2.4M
2.5M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$146.28
N/A
Revenue Next Year
$24.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.85
52 Week High
$8.62
$28.60

Technical Indicators

Market Signals
Indicator
SXTP
ARTL
Relative Strength Index (RSI) 36.03 46.13
Support Level $1.19 $1.35
Resistance Level $1.49 $4.32
Average True Range (ATR) 0.40 1.31
MACD -0.09 -0.05
Stochastic Oscillator 7.08 23.91

Price Performance

Historical Comparison
SXTP
ARTL

About SXTP 60 Degrees Pharmaceuticals Inc.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: